Nastech Amends Previous Flu Tx Timeline, Expects RNAi Unit Spinout by Mid-Year 2008

Although Nastech had previously expected to file an IND for its RNAi-based flu drug this year, the company now says that it isn’t giving guidance on when the filing will occur.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.